Camp 4 Therapeutics Corp (CAMP)

Apr 30, 2026

Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union

Apr 30, 2026

Apr 28, 2026

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times

Apr 28, 2026

Apr 28, 2026

CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan

Apr 28, 2026

Apr 26, 2026

Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN

Apr 26, 2026

Apr 23, 2026

CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan

Apr 23, 2026

Apr 23, 2026

[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan

Apr 23, 2026

Apr 18, 2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm

Apr 18, 2026

Apr 17, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat

Apr 17, 2026

Apr 17, 2026

Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan

Apr 17, 2026

Apr 15, 2026

Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union

Apr 15, 2026

Apr 15, 2026

CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw - MarketBeat

Apr 15, 2026

Apr 14, 2026

Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia

Apr 14, 2026

Apr 14, 2026

Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com

Apr 14, 2026

Apr 13, 2026

CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - MarketBeat

Apr 13, 2026

Apr 09, 2026

Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union

Apr 09, 2026

Apr 08, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 08, 2026

Apr 07, 2026

CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill

Apr 07, 2026

Apr 06, 2026

Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union

Apr 06, 2026

Apr 06, 2026

Is CAMP4 (CAMP) Stock Good for Beginners | Price at $4.72, Up 5.59%Aggressive Growth Stocks - Newser

Apr 06, 2026

Apr 03, 2026

Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan

Apr 03, 2026

Apr 03, 2026

Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan

Apr 03, 2026

Apr 03, 2026

Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan

Apr 03, 2026

Apr 03, 2026

Camp4 Therapeutics Corp (CAMP) CEO granted 580,000 stock options at $4.46 - Stock Titan

Apr 03, 2026

Apr 03, 2026

Camp4 Therapeutics (CAMP) director awarded 56,000 stock options at $4.46 strike - Stock Titan

Apr 03, 2026

Apr 03, 2026

Camp4 Therapeutics (CAMP) director Michael MacLean files initial Form 3 - Stock Titan

Apr 03, 2026

Apr 03, 2026

Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm

Apr 03, 2026

Apr 03, 2026

CAMP Stock Analysis: CAMP4 Therapeutics biotech review at 4.47 small daily gain - Newser

Apr 03, 2026

Apr 02, 2026

Leerink raises CAMP4 Therapeutics price target on CMP-002 progress By Investing.com - Investing.com South Africa

Apr 02, 2026

Apr 02, 2026

Leerink raises CAMP4 Therapeutics price target on CMP-002 progress - Investing.com

Apr 02, 2026

Apr 01, 2026

CAMP PE Ratio & Valuation, Is CAMP Overvalued - Intellectia AI

Apr 01, 2026

Mar 30, 2026

Aug Swings: Should value investors consider Camp4 Therapeutics Corporation2026 Earnings Surprises & Daily Entry Point Alerts - baoquankhu1.vn

Mar 30, 2026

Mar 24, 2026

CAMP4 Therapeutics Adds Veteran CFO MacLean to Board - TipRanks

Mar 24, 2026

Mar 24, 2026

CAMP4 Therapeutics Corporation Files Form 8-K for NASDAQ Listing – Company Details and Key Information (March 2026) - Minichart

Mar 24, 2026

Mar 24, 2026

CAMP4 Appoints Michael MacLean to its Board of Directors - Bitget

Mar 24, 2026

Mar 24, 2026

Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation - Investing.com Australia

Mar 24, 2026

Mar 24, 2026

Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation By Investing.com - Investing.com South Africa

Mar 24, 2026

Mar 24, 2026

CAMP4 Therapeutics appoints Michael MacLean to board of directors - investing.com

Mar 24, 2026

Mar 24, 2026

CAMP4 Therapeutics appoints Michael MacLean to board of directors By Investing.com - Investing.com UK

Mar 24, 2026

Mar 24, 2026

Camp4 Therapeutics appoints Michael MacLean as director, joins Audit and Compensation Committees - TradingView

Mar 24, 2026

Mar 24, 2026

Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push - Traders Union

Mar 24, 2026

Mar 24, 2026

Biotech CAMP4 taps veteran CFO as it pushes SYNGAP1 drug to trial - Stock Titan

Mar 24, 2026

Mar 24, 2026

New CAMP4 (NASDAQ: CAMP) director MacLean joins, receives option grant - Stock Titan

Mar 24, 2026

Mar 21, 2026

If You Invested $1,000 in Camp4 Therapeutics Corp. (CAMP) - Stock Titan

Mar 21, 2026

Mar 11, 2026

Camp4 Therapeutics (CAMP) holder Enavate cuts stake to 4.8% of shares - Stock Titan

Mar 11, 2026

Mar 09, 2026

EVTL Technical Analysis & Price Forecast - Intellectia AI

Mar 09, 2026

Mar 07, 2026

Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP) - Seeking Alpha

Mar 07, 2026

Mar 06, 2026

CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times

Mar 06, 2026

Mar 06, 2026

Biotech firm CAMP4 lines up 3 healthcare investor events - Stock Titan

Mar 06, 2026

Mar 06, 2026

Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target - Investing.com India

Mar 06, 2026

Mar 06, 2026

Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target By Investing.com - Investing.com Australia

Mar 06, 2026